164 related articles for article (PubMed ID: 38637844)
41. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
[TBL] [Abstract][Full Text] [Related]
42. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
Chang JY; Mehran RJ; Feng L; Verma V; Liao Z; Welsh JW; Lin SH; O'Reilly MS; Jeter MD; Balter PA; McRae SE; Berry D; Heymach JV; Roth JA;
Lancet Oncol; 2021 Oct; 22(10):1448-1457. PubMed ID: 34529930
[TBL] [Abstract][Full Text] [Related]
43. Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model.
Louie AV; Haasbeek CJ; Mokhles S; Rodrigues GB; Stephans KL; Lagerwaard FJ; Palma DA; Videtic GM; Warner A; Takkenberg JJ; Reddy CA; Maat AP; Woody NM; Slotman BJ; Senan S
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):82-90. PubMed ID: 26138912
[TBL] [Abstract][Full Text] [Related]
44. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer.
Widder J; Postmus D; Ubbels JF; Wiegman EM; Langendijk JA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e291-7. PubMed ID: 21640503
[TBL] [Abstract][Full Text] [Related]
45. Correlation of biologically effective dose and the tumor control in Stage I (<5 cm) non-small cell lung cancer with stereotactic ablative radiotherapy: a single institutional cohort study.
Jeon W; Ahn SJ; Kim YC; Oh IJ; Park CK; Jeong JU; Yoon MS; Song JY; Nam TK; Chung WK
Jpn J Clin Oncol; 2018 Feb; 48(2):144-152. PubMed ID: 29194510
[TBL] [Abstract][Full Text] [Related]
46. Dose-volume-response analysis in stereotactic radiotherapy for early lung cancer.
Suzuki O; Mitsuyoshi T; Miyazaki M; Teshima T; Nishiyama K; Ubbels JF; Bolt RA; Langendijk JA; Widder J
Radiother Oncol; 2014 Aug; 112(2):262-6. PubMed ID: 25107554
[TBL] [Abstract][Full Text] [Related]
47. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
Phillips I; Sandhu S; Lüchtenborg M; Harden S
Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
[TBL] [Abstract][Full Text] [Related]
48. Comparison of Long-term Survival of Patients With Early-Stage Non-Small Cell Lung Cancer After Surgery vs Stereotactic Body Radiotherapy.
Chi A; Fang W; Sun Y; Wen S
JAMA Netw Open; 2019 Nov; 2(11):e1915724. PubMed ID: 31747032
[TBL] [Abstract][Full Text] [Related]
49. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
Dubaere E; Goffaux M; Wanet M; Bihin B; Gheldof C; Demoulin AS; Bolly A; Bustin F; Duplaquet F; Baugnee PE; Gustin M; Hers V; Maisin F; Marchand E; Ocak S; Pirard L; Vancutsem O; Van Neck E; Vandermoten G; Zaharia L; Remouchamps V
BMC Cancer; 2019 Jun; 19(1):639. PubMed ID: 31253136
[TBL] [Abstract][Full Text] [Related]
50. Prior Treatment for Non-small Cell Lung Cancer Is Associated With Improved Survival in Patients who Undergo Definitive Stereotactic Body Radiation Therapy for a Subsequent Lung Malignancy: A Retrospective Multivariate and Matched Pair Analysis.
Farrugia MK; Jun Ma S; Hennon MW; Nwogu CE; Dexter EU; Picone AL; Demmy TL; Gomez-Suescun JA; Fung-Kee-Fung S; Yendamuri SS; Singh AK
Am J Clin Oncol; 2021 Jan; 44(1):18-23. PubMed ID: 33264123
[TBL] [Abstract][Full Text] [Related]
51. Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy.
Liu J; Hui C; Ladbury C; Waddington T; Erhunmwunsee L; Raz D; Kim J; Salgia R; Chenery S; Pearlstein D; Schwer A; Amini A
Clin Lung Cancer; 2021 Sep; 22(5):e678-e683. PubMed ID: 33712362
[TBL] [Abstract][Full Text] [Related]
52. SABR vs. Limited Resection for Non-small Cell Lung Cancer: Are We Closer to an Answer?
Chen H; Louie AV
Curr Treat Options Oncol; 2016 Jun; 17(6):27. PubMed ID: 27098533
[TBL] [Abstract][Full Text] [Related]
53. Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer - A Done Deal?
Gulstene S; Ruwanpura T; Palma D; Joseph N
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):733-740. PubMed ID: 36050221
[TBL] [Abstract][Full Text] [Related]
54. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
[TBL] [Abstract][Full Text] [Related]
55. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
[TBL] [Abstract][Full Text] [Related]
56. SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC.
Nyman J; Hallqvist A; Lund JÅ; Brustugun OT; Bergman B; Bergström P; Friesland S; Lewensohn R; Holmberg E; Lax I
Radiother Oncol; 2016 Oct; 121(1):1-8. PubMed ID: 27600155
[TBL] [Abstract][Full Text] [Related]
57. Role of stereotactic body radiotherapy for early-stage non-small-cell lung cancer in patients borderline for surgery due to impaired pulmonary function.
Tomita N; Okuda K; Kita N; Niwa M; Hashimoto S; Murai T; Ishikura S; Nakanishi R; Shibamoto Y
Asia Pac J Clin Oncol; 2022 Dec; 18(6):634-641. PubMed ID: 35098662
[TBL] [Abstract][Full Text] [Related]
58. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
Yan SX; Qureshi MM; Dyer M; Truong MT; Mak KS
Lung Cancer; 2019 May; 131():147-153. PubMed ID: 31027693
[TBL] [Abstract][Full Text] [Related]
59. Stereotactic body radiotherapy and treatment at a high volume facility is associated with improved survival in patients with inoperable stage I non-small cell lung cancer.
Koshy M; Malik R; Mahmood U; Husain Z; Sher DJ
Radiother Oncol; 2015 Feb; 114(2):148-54. PubMed ID: 25586951
[TBL] [Abstract][Full Text] [Related]
60. Can dosimetry affect local control and survival in patients with early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? An analysis of the UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Acta Oncol; 2021 Apr; 60(4):505-512. PubMed ID: 33491521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
